Skip to main content
. 2020 Mar 18;10(3):e034716. doi: 10.1136/bmjopen-2019-034716

Figure 7.

Figure 7

Sensitivity analyses: incremental costs per person over a lifetime for the All Testing strategy versus the No Testing strategy. GCK, glucokinase; HBGM, home blood glucose monitoring; HNF1/4A, hepatocyte nuclear factor 1/4 alpha.